Need access to NeoLink? Contact your Sales rep or our Client Services team at 866.776.5907, Option 3
June 18, 2025
Introducing PanTracer Tissue
We’re excited to announce the launch of PanTracer Tissue,the enhanced and rebranded version of our pan-solid tumor NGS panel, Neo Comprehensive – Solid Tumor, on June 23rd.
The product evolution represents more than a new name. It reflects our commitment to evolving with the needs of oncology care—offering tests that are practical, powerful, and designed to support real-world clinical decisions.
PanTracer Tissue offers a tissue-based CGP approach, providing deep insights into tumor genome from solid-tumor biopsy samples, helping oncologists make precise, actionable therapy decisions. And soon, in an expanded offering, PanTracer Tissue + HRD will be available for patients with ovarian cancer.
We’re proud to share PanTracer Tissue with you—the next evolution of our pan-solid tumor NGS panel, redesigned and refined to meet the needs of today’s oncology landscape.
More insight. More flexibility. One powerful solution.
Learn more about PanTracer Tissue on our webpage.
Neo Comprehensive – Solid Tumor will transition to PanTracer Tissue on June 23rd. Orders submitted prior to June 22nd but not yet reported will also be transitioned to PanTracer Tissue.
Update to NeoGenomics Specimen Transport Kits
The NeoGenomics specimen collection and transport kits have a new look! The current red- and blue-colored kits will be phased out and replaced with our new green kits, pictured to the left. 
Along with the new look, we have taken this opportunity to improve our kit’s sustainability, utilizing materials that are more environmentally friendly.
These new transport kits will be phased in over the next several months. You can expect to see the new tissue transport kits and liquid biopsy kits in the coming weeks. Specimen transport kits for bone marrow, peripheral blood, and Bladder FISH will be phased in later this summer and into the fall.
If you have any questions or concerns, please reach out to your local sales representative or contact Client Services at 866.776.5907, Option 3.
IHC stain interpretation updates
As part of our ongoing commitment to advancing oncology diagnostics, we are optimizing our test menu to ensure you have access to the most clinically advanced solutions available.
As a reminder, Effective June 30, 2025, prognostic interpretation for select IHC stains will no longer be offered. These stains will continue to be available as technical component only. If interpretation is required, we encourage you to request a full consultation through our team of highly trained anatomic pathologists.
The full list of IHC test updates is available here.
For additional information on our IHC offerings and to view our complete testing portfolio, please visit NeoGenomics.com.
If you have any questions or concerns, contact your local NeoGenomics Sales Consultant or our Client Services team at 866.776.5907, option 3.